267 related articles for article (PubMed ID: 8884144)
21. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
Golub SH; Forsythe AB; Morton DL
Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
[TBL] [Abstract][Full Text] [Related]
22. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Baars A; Claessen AM; van den Eertwegh AJ; Gall HE; Stam AG; Meijer S; Giaccone G; Meijer CJ; Scheper RJ; Wagstaff J; Vermorken JB; Pinedo HM
Ann Oncol; 2000 Aug; 11(8):965-70. PubMed ID: 11038032
[TBL] [Abstract][Full Text] [Related]
23. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
24. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.
Lui VK; Karpuchas J; Dent PB; McCulloch PB; Blajchman MA
Br J Cancer; 1975 Sep; 32(3):323-30. PubMed ID: 1233077
[TBL] [Abstract][Full Text] [Related]
25. Multiple cutaneous malignant melanomas with features of primary melanoma.
Unger SW; Wanebo HJ; Cooper PH
Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
[TBL] [Abstract][Full Text] [Related]
26. Monocyte response receptors in BCG driven delayed type hypersensitivity to tuberculin.
Strapagiel D; Kasztalska K; Druszczyńska M; Kowalewicz-Kulbat M; Vrba A; Matusiak A; Chmiela M; Rudnicka W
Folia Histochem Cytobiol; 2008; 46(3):353-9. PubMed ID: 19056540
[TBL] [Abstract][Full Text] [Related]
27. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
28. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
32. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
33. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
34. Purified protein derivative response in juvenile idiopathic arthritis.
Kiray E; Kasapcopur O; Bas V; Kamburoglu-Goksel A; Midilli K; Arisoy N; Tastan Y
J Rheumatol; 2009 Sep; 36(9):2029-32. PubMed ID: 19648302
[TBL] [Abstract][Full Text] [Related]
35. Neonatal bacillus Calmette-Guerin vaccination and environmental mycobacteria in sensitizing antimycobacterial activity of macrophages.
Periasamy M; Datta M; Kannapiran M; Ramanathan VD; Venkatesan P
Am J Med Sci; 2014 Jul; 348(1):57-64. PubMed ID: 24374737
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer.
Lebret T; Becette V; Hervé JM; Molinié V; Barré P; Lugagne PM; Gentille A; Baglin AC; Botto H
Eur Urol; 2000 Jun; 37(6):654-9. PubMed ID: 10828663
[TBL] [Abstract][Full Text] [Related]
37. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
Cascinelli N; Rümke P; MacKie R; Morabito A; Bufalino R
Cancer Immunol Immunother; 1989; 28(4):282-6. PubMed ID: 2702680
[TBL] [Abstract][Full Text] [Related]
38. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
39. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
40. Intralesional immunotherapy of melanoma with BCG.
Rosenberg SA; Rapp HJ
Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
